Cardinal Health — May 1, 2025 release

Cardinal Health Page 3 Fiscal year 2025 outlook 2 The company raised and narrowed its fiscal 2025 guidance range for non-GAAP diluted earnings per share attributable to Cardinal Health, Inc. to $8.05 to $8.15, from $7.85 to $8.00. The updated fiscal 2025 guidance reflects: • Increased outlook for Pharmaceutical and Specialty Solutions segment profit to 11.5% to 12.5% growth, from 10% to 12% growth previously • Increased outlook for Other segment profit to 16% to 18% growth, from ~10% growth previously, driven by stronger organic performance and the completed acquisition of Advanced Diabetes Supply Group • Narrowed outlook for GMPD segment profit to $130 million to $140 million, from $130 million to $150 million previously • Narrowed outlook for interest and other expense to a range of $200 million to $215 million, from $200 million to $230 million previously • Narrowed outlook for non-GAAP effective tax rate of 23% to 23.5%, from 23% to 24% previously • Updated outlook for diluted weighted average shares outstanding to ~242 million, from ~243 million previously, reflecting recent share repurchases Fiscal year 2026 update 2 Cardinal Health anticipates double-digit non-GAAP EPS growth in fiscal 2026, despite the evolving macro environment conditions. The company continues to expect strong segment profit growth in Pharmaceutical and Specialty Solutions and across its three operating segments reported in Other. In the face of the macro uncertainty, the company is updating its expectations for fiscal 2026 GMPD segment profit, which it now expects to be at